TABLE 1.
In vivo tumorigenicity of established HTLV-1-transformed cell lines
| Cell line | Origin | Recipient (age) | No. of rats | Inoculation routea | Finding(s)b |
|---|---|---|---|---|---|
| F344-S1 | F344 | F344 (NBc) | 4 | i.p. | NS |
| F344 (4 wk) | 2 | s.c. | NS | ||
| nu/nu (4 wk) | 5 | s.c. | Progressive s.c. tumor with multiple metastases | ||
| nu/nu (4 wk) | 1 | i.p. | Progressive i.p. multiple tumors | ||
| nu/nu (4 wk) | 1 | i.v. | Progressive systemic multiple tumors | ||
| TARS-1 | WKAH | WKAH (4 wk) | 5 | s.c. | Transient s.c. tumor (1 wk)d |
| WKAH (4 wk) | 1 | i.p. | NS | ||
| nu/nu (4 wk) | 3 | s.c. | Progressive s.c. tumor with lung metastasis | ||
| nu/nu (4 wk) | 1 | i.p. | Progressive i.p. multiple tumors | ||
| nu/nu (4 wk) | 1 | i.v. | Progressive systemic multiple tumors | ||
| TART-1 | WKAH | WKAH (NB) | 9 | s.c. | NS |
| nu/nu (4 wk) | 1 | s.c. | NS | ||
| W7TM-1 | WKAH | WKAH (NB) | 7 | s.c. | NS |
| nu/nu (4 wk) | 1 | s.c. | NS | ||
| MT-2 | Human | nu/+ (4 wk) | 4 | i.v. | NS |
| nu/nu (4 wk) | 4 | i.v. | NS | ||
| F344 (4 wk) | 4 | i.p. | NS |
a
i.p., intraperitoneal; s.c., subcutaneous; i.v., intravenous.
b
Autopsy was performed 4 to 10 weeks after inoculation. NS, no symptoms.
c
NB, newborn.
d
Tumor cell growth was observed for the first week after inoculation.